Discovery of 2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β Agonist in Clinical Trials for the Treatment of Dyslipidemia-Reference-Cited by-同舟云学术

Discovery of 2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β Agonist in Clinical Trials for the Treatment of Dyslipidemia

Published:2014-04-08 Issue:10 Volume:57 Page:3912-3923
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Kelly Martha J.¹,Pietranico-Cole Sherrie²,Larigan J. Douglas²,Haynes Nancy-Ellen²,Reynolds Charles H.³,Scott Nathan²,Vermeulen John²,Dvorozniak Mark²,Conde-Knape Karin²,Huang Kuo-Sen²,So Sung-Sau²,Thakkar Kshitij²,Qian Yimin²,Banner Bruce²,Mennona Frank²,Danzi Sara⁴,Klein Irwin⁵,Taub Rebecca¹,Tilley Jefferson²

Affiliation:

1. Madrigal Pharmaceuticals, Inc., Fort Washington, Pennsylvania 19034, United States

2. Hoffmann-La Roche, Inc., Nutley, New Jersey 07110, United States

3. Gfree Bio LLC, Doylestown, Pennsylvania 18902, United States

4. Queensborough Community College, Bayside, New York 11364, United States

5. New York University School of Medicine, New York, New York 10016, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm4019299